|
|
|
|
Ranbaxy Announces Settlement of Actos (Pioglitazone Hydrochloride) Patent Litigation
JACKSONVILLE, Fla., March 15 /PRNewswire/ -- Ranbaxy Laboratories Limited, along with its wholly owned subsidiary Ranbaxy Pharmaceuticals Inc.(collectively, 'Ranbaxy'), announced today that they have reached an agreement with Takeda Pharmaceutical Company...
|
|
|
Pioglitazone Decreases Plasma CETP Mass in Type 2 Diabetics
_ Pioglitazone Decreases Plasma CETP Mass in Type 2 Diabetics.
|
|
|
Pioglitazone Decreases Plasma CETP Mass in Type 2 Diabetics
_ Pioglitazone Decreases Plasma CETP Mass in Type 2 Diabetics.
|
|
|
Mylan Announces First-to-File Opportunity Settlement Agreements for Actoplus Met(R) and Actos(R)
-- Mylan Inc.(Nasdaq: MYL) today announced that it has entered into settlement agreements with Takeda Pharmaceutical Co. related to two treatments for type 2 diabetes: Actoplus Met(), 15 mg/500 mg and 15 mg/850 mg, known generically as Pioglitazone...
|
|
|
Mylan Announces First-to-File Opportunity Settlement Agreements for Actoplus Met(R) and Actos(R)
Mylan Inc.(Nasdaq: MYL) today announced that it has entered into settlement agreements with Takeda Pharmaceutical Co. related to two treatments for type 2 diabetes: Actoplus Met, 15 mg/500 mg and 15 mg/850 mg, known generically as Pioglitazone...
|
|
|
Mylan Announces First-to-File Opportunity Settlement Agreements for Actoplus Met(R) and Actos(R)
Mylan Inc.(Nasdaq: MYL) today announced that it has entered into settlement agreements with Takeda Pharmaceutical Co. related to two treatments for type 2 diabetes: Actoplus Met, 15 mg/500 mg and 15 mg/850 mg, known generically as Pioglitazone...
|
|
|
Mylan Announces First-to-File Opportunity Settlement Agreements for Actoplus Met(R) and Actos(R)
Mylan Inc.(Nasdaq: MYL) today announced that it has entered into settlement agreements with Takeda Pharmaceutical Co. related to two treatments for type 2 diabetes: Actoplus Met(R), 15 mg/500 mg and 15 mg/850 mg, known generically as Pioglitazone...
|
|
|
Actoplus Met and Actos: Mylan enters into settlement agreements with Takeda Pharmaceutical
Mylan Inc.(Nasdaq: MYL) today announced that it has entered into settlement agreements with Takeda Pharmaceutical Co. related to two treatments for type 2 diabetes: Actoplus Met, 15 mg/500 mg and 15 mg/850 mg, known generically as Pioglitazone...
|
|
|
Mylan (MYL) Settles with Takeda Pharma Regarding Two Type 2 Diabetes Treatments
Mylan Inc.(NASDAQ: MYL) today announced that it has entered into settlement agreements with Takeda Pharmaceutical Co. related to two treatments for type 2 diabetes: Actoplus Met, 15 mg/500 mg and 15 mg/850 mg, known generically as Pioglitazone...
|
|
|
Ranbaxy Announces Settlement of Actos(R) (Pioglitazone Hydrochloride) Patent Litigation
JACKSONVILLE, Fla., March 15 /PRNewswire/ Ranbaxy Laboratories Limited, along with its wholly owned subsidiary Ranbaxy Pharmaceuticals Inc.(collectively, 'Ranbaxy'), announced today that they have reached an agreement with Takeda Pharmaceutical Company...
|
|
|
Ranbaxy Announces Settlement of Actos(R) (Pioglitazone Hydrochloride) Patent Litigation
Companies mentioned in this article: Ranbaxy Laboratories Limited JACKSONVILLE, Fla., March 15 /PRNewswire/ -- Ranbaxy Laboratories Limited, along with its wholly owned subsidiary Ranbaxy Pharmaceuticals Inc.(collectively, 'Ranbaxy'), announced today that...
|
|
|
Ranbaxy Announces Settlement Of Actos(R) (Pioglitazone Hydrochloride) Patent Litigation
Jacksonville, FL -- /PRNewswire/ -- Ranbaxy Laboratories Limited, along with its wholly owned subsidiary Ranbaxy Pharmaceuticals Inc.(collectively, "Ranbaxy"), announced today that they have reached an agreement with Takeda Pharmaceutical Company Limited and...
|
|
|
Ranbaxy resolves generic Actos patent litigation
Ranbaxy Laboratories Limited, along with its wholly owned subsidiary Ranbaxy Pharmaceuticals Inc.(collectively, "Ranbaxy"), announced today that they have reached an agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North...
|
|
|
Ranbaxy, Takeda tie up to resolve patent litigation
Ranbaxy Laboratories and its wholly-owned subsidiary, Ranbaxy Pharmaceuticals, have reached an agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America, for resolving outstanding patent litigation related to Ranbaxy's...
|
|
|
Watson Announces Actos(R) Patent Challenge Settlement
MORRISTOWN, N.J., March 10 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc.(NYSE: WPI), today announced that it has reached a settlement agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving outstanding...
|
|
|
Watson Announces Actos(R) Patent Challenge Settlement
MORRISTOWN, N.J., March 10 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc.(NYSE: WPI), today announced that it has reached a settlement agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving outstanding...
|
|
|
Watson Announces Actos Patent Challenge Settlement
/PRNewswire via COMTEX/ -- Watson Pharmaceuticals, Inc.(NYSE: WPI), today announced that it has reached a settlement agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving outstanding patent litigation related...
|
|
|
Watson Announces Actos Patent Challenge Settlement
Morristown, NJ /PRNewswire/ -- Watson Pharmaceuticals, Inc.(NYSE: WPI), today announced that it has reached a settlement agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving outstanding patent litigation...
|
|
|
Watson Pharmaceuticals resolves Actos patent litigation
Watson Pharmaceuticals, Inc.(NYSE: WPI), today announced that it has reached a settlement agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving outstanding patent litigation related to Watson's generic...
|
|
|
Watson Announces Actos(R) Patent Challenge Settlement
MORRISTOWN, N.J., March 10 /PRNewswire-FirstCall/ Watson Pharmaceuticals, Inc.(NYSE: WPI), today announced that it has reached a settlement agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving outstanding...
|
|
|
Takeda Pharmaceutical signs licensing agreement with Watson Pharm...
Companies: Takeda Pharmaceutical Co Ltd (TKPHF), Watson Pharmaceuticals, Inc.(WPI) Watson Pharmaceuticals, Inc., a US-based specialty pharmaceutical company, has reached a settlement agreement with Takeda Pharmaceutical Company Limited (Takeda) and Takeda...
|
|
|
Watson Pharmaceuticals settles patent litigation with Takeda Phar...
Companies: Takeda Pharmaceutical Co Ltd (TKPHF), Watson Pharmaceuticals, Inc.(WPI) Watson Pharmaceuticals, Inc., a US-based specialty pharmaceutical company, has reached a settlement agreement with Takeda Pharmaceutical Company Limited (Takeda) and Takeda...
|
|
|
Takeda Pharmaceutical signs licensing agreement with Watson Pharmaceuticals for Actos(R)
Watson Pharmaceuticals, Inc., a US-based specialty pharmaceutical company, has reached a settlement agreement with Takeda Pharmaceutical Company Limited (Takeda) and Takeda Pharmaceuticals North America, Inc.(TPNA) resolving outstanding patent litigation...
|
|
|
Watson Pharmaceuticals settles patent litigation with Takeda Pharmaceutical for Actos(R)
Watson Pharmaceuticals, Inc., a US-based specialty pharmaceutical company, has reached a settlement agreement with Takeda Pharmaceutical Company Limited (Takeda) and Takeda Pharmaceuticals North America, Inc.(TPNA) resolving outstanding patent litigation...
|
|
|
Watson Announces Actos(R) Patent Challenge Settlement
MORRISTOWN, N.J., March 10 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc.(NYSE: WPI), today announced that it has reached a settlement agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving outstanding...
|
